RYTM vs. TGTX
RYTM (Rhythm Pharmaceuticals, Inc.) and TGTX (TG Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, RYTM returned 35.54%/yr vs 2.66%/yr for TGTX. At a 0.33 correlation, their price movements are largely independent.
Performance
RYTM vs. TGTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RYTM achieves a -20.86% return, which is significantly lower than TGTX's 34.55% return.
RYTM
- 1D
- 0.43%
- 1M
- -1.02%
- YTD
- -20.86%
- 6M
- -19.04%
- 1Y
- 28.99%
- 3Y*
- 68.05%
- 5Y*
- 35.54%
- 10Y*
- —
TGTX
- 1D
- 9.47%
- 1M
- 12.34%
- YTD
- 34.55%
- 6M
- 26.89%
- 1Y
- 10.16%
- 3Y*
- 14.73%
- 5Y*
- 2.66%
- 10Y*
- 17.63%
RYTM vs. TGTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RYTM Rhythm Pharmaceuticals, Inc. | -20.86% | 91.21% | 21.78% | 57.86% | 191.78% | -66.43% | 29.49% | -14.58% | -7.50% | -3.13% |
TGTX TG Therapeutics, Inc. | 34.55% | -0.96% | 76.23% | 44.38% | -37.74% | -63.48% | 368.65% | 170.73% | -50.00% | -33.06% |
Correlation
The correlation between RYTM and TGTX is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.36 |
Correlation (All Time) Calculated using the full available price history since Oct 6, 2017 | 0.33 |
Fundamentals
RYTM:
$5.76B
TGTX:
$6.42B
RYTM:
-$3.10
TGTX:
$2.87
RYTM:
25.64
TGTX:
9.21
RYTM:
702.55
TGTX:
11.01
RYTM:
$217.17M
TGTX:
$700.35M
RYTM:
$194.16M
TGTX:
$581.54M
RYTM:
-$182.86M
TGTX:
$156.88M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RYTM vs. TGTX — Risk / Return Rank
RYTM
TGTX
RYTM vs. TGTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Rhythm Pharmaceuticals, Inc. (RYTM) and TG Therapeutics, Inc. (TGTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RYTM | TGTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.29 | ||
| Sortino ratioReturn per unit of downside risk | +0.68 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.08 | +0.07 |
| Calmar ratioReturn relative to maximum drawdown | 0.82 | 0.30 | +0.52 |
| Martin ratioReturn relative to average drawdown | 1.96 | 0.52 | +1.44 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| RYTM | TGTX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.51 | 0.22 | +0.29 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.47 | 0.03 | +0.44 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.20 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.18 | -0.05 | +0.23 |
Drawdowns
RYTM vs. TGTX - Drawdown Comparison
The maximum RYTM drawdown since its inception was -92.10%, smaller than the maximum TGTX drawdown of -99.52%. Use the drawdown chart below to compare losses from any high point for RYTM and TGTX.
Loading charts...
Drawdown Indicators
| RYTM | TGTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.10% | -99.52% | +7.42% |
Max Drawdown (1Y)Largest decline over 1 year | -35.54% | -34.12% | -1.42% |
Max Drawdown (3Y)Largest decline over 3 years | -35.54% | -76.95% | +41.41% |
Max Drawdown (5Y)Largest decline over 5 years | -85.49% | -90.75% | +5.26% |
Max Drawdown (10Y)Largest decline over 10 years | — | -93.19% | — |
Current DrawdownCurrent decline from peak | -27.98% | -82.82% | +54.84% |
Average DrawdownAverage peak-to-trough decline | -32.19% | -91.47% | +59.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.81% | 19.60% | -4.79% |
Volatility
RYTM vs. TGTX - Volatility Comparison
The current volatility for Rhythm Pharmaceuticals, Inc. (RYTM) is 16.84%, while TG Therapeutics, Inc. (TGTX) has a volatility of 19.58%. This indicates that RYTM experiences smaller price fluctuations and is considered to be less risky than TGTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RYTM | TGTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.84% | 19.58% | -2.74% |
Volatility (6M)Calculated over the trailing 6-month period | 36.79% | 33.27% | +3.52% |
Volatility (1Y)Calculated over the trailing 1-year period | 57.37% | 46.62% | +10.75% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 76.41% | 87.72% | -11.31% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 70.99% | 86.87% | -15.88% |
Dividends
RYTM vs. TGTX - Dividend Comparison
Neither RYTM nor TGTX has paid dividends to shareholders.
Financials
RYTM vs. TGTX - Financials Comparison
This section allows you to compare key financial metrics between Rhythm Pharmaceuticals, Inc. and TG Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RYTM vs. TGTX - Profitability Comparison
RYTM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported a gross profit of 52.96M and revenue of 60.11M. Therefore, the gross margin over that period was 88.1%.
TGTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a gross profit of 171.41M and revenue of 204.92M. Therefore, the gross margin over that period was 83.7%.
RYTM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported an operating income of -52.36M and revenue of 60.11M, resulting in an operating margin of -87.1%.
TGTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported an operating income of 34.80M and revenue of 204.92M, resulting in an operating margin of 17.0%.
RYTM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported a net income of -56.74M and revenue of 60.11M, resulting in a net margin of -94.4%.
TGTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a net income of 19.78M and revenue of 204.92M, resulting in a net margin of 9.7%.
Frequently Asked Questions
RYTM and TGTX have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TGTX has higher volatility (19.58%) compared to RYTM (16.84%). In terms of maximum drawdown, RYTM dropped -92.10% vs TGTX's -99.52%.
RYTM currently has the higher Sharpe Ratio (0.51 vs 0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RYTM and TGTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer